Efficacy of preoperative inhaled LAMA/LABA combinations in patients with lung cancer and untreated COPD
- 1 December 2021
- journal article
- research article
- Published by Edizioni Minerva Medica in Minerva Surgery
- Vol. 76 (6) , 592-597
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with a high incidence of postoperative pulmonary complications (PPCs). When untreated COPD is found before lung cancer surgery, we have been actively intervening therapeutically with inhaled long-acting muscarinic antagonist (LAMA)/long-acting beta 2-agonist (LABA) combinations. We investigated the efficacy of preoperative LAMA/LABA treatment. METHODS: We reviewed data from 261 patients who underwent pulmonary resection for primary lung cancer. Of these, 59 patients showed unrecognized obstructive ventilatory impairment on respiratory function testing. We administered inhaled drugs for 38 patients, of whom 22 patients treated with LAMA/LABA combinations and diagnosed with COPD were retrospectively analyzed regarding improvement of respiratory function and postoperative course. RESULTS: Median duration of LAMA/LABA treatment was 19.5 days (interquartile range (IQR), 10.5-28.3 days). Percentage predicted vital capacity (%VC) (pretreatment: 95.6%, IQR 91.9-111.7 vs. posttreatment 102.8%, IQR 92.3113.0), forced expiratory volume in 1 s (FEV1) (1.76 L, 1.43-2.12 vs. 2.00 L, 1.78-2.40), forced VC (FVC) (2.96 L, 2.64-3.47 vs. 3.22 L, 2.95-3.74) and percentage predicted FEV1 (80.1%, 68.4-97.0 vs. 91.6%, 80.3-101.9) were all significantly improved (P 0.05 each). FEV1/FVC tended to be improved, but not significantly. No significant difference in improvement of respiratory function was seen between short-term (<= 2 weeks) and normal-term ( 2 weeks) treatment. PPCs occurred in 4 of 22 patients (18.2%), showing no significant difference compared to patients with COPD previously treated with inhaled drugs (2/20; 10.0%). CONCLUSIONS: Respiratory function is improved by preoperative LAMA/LABA treatment even in the short term. Starting treatment allows even COPD patients diagnosed on preoperative screening to experience the same frequency of PPCs as previously treated patients.Keywords
This publication has 26 references indexed in Scilit:
- Impact of COPD on Postoperative OutcomesChest, 2013
- Trends in the Prevalence of Obstructive and Restrictive Lung Function Among Adults in the United StatesChest, 2013
- RETRACTED ARTICLE: Inhaled tiotropium to prevent postoperative cardiopulmonary complications in patients with newly diagnosed chronic obstructive pulmonary disease requiring lung cancer surgerySurgery Today, 2013
- Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trialEuropean Journal of Cardio-Thoracic Surgery, 2011
- Prediction of Postoperative Pulmonary Complications in a Population-based Surgical CohortAnesthesiology, 2010
- QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax, 2010
- Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPDRespirology, 2009
- Influence of chronic obstructive pulmonary disease on postoperative lung function and complications in patients undergoing operations for primary non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2007
- Operative Mortality and Respiratory Complications After Lung Resection for Cancer: Impact of Chronic Obstructive Pulmonary Disease and Time TrendsThe Annals of Thoracic Surgery, 2006
- COPD in Japan: the Nippon COPD Epidemiology studyRespirology, 2004